Mayo Clinic Plans 2012 Launch for Sequencing-Based Colon Cancer Panel
May 10, 2011
Mayo Clinic Plans 2012 Launch for Sequencing-Based Colon Cancer Panel
Like other pioneers in sequencing-based diagnostics, the Mayo team is grappling with questions such as how to deal with mutations of unknown significance, how to return results to patients, and whether results need to be verified with Sanger sequencing.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- GenomeWeb Feature: Will the Future of Genomics be Consumer Driven?
March 4, 2013 / GenomeWeb Daily News - Illumina Growing Clinical and Dx Business with Submission of MiSeqDx, Two CF Assays to FDA
January 9, 2013 / Clinical Sequencing News - Life Tech Sees Clinical Promise for NGS Panels, Exomes; Says Multiple Platforms to Drive Dx Strategy
August 1, 2012 / Clinical Sequencing News - Quest Study Finds Sanger-based BRAF Mutation Test More Sensitive than Roche's Cobas Test
June 13, 2012 / Pharmacogenomics Reporter - Sequenom Performs More than 1,000 T21 Tests, Reports 23 Percent Revenue Increase for 2011
January 18, 2012 / Clinical Sequencing News